{"id":"https://openalex.org/W2099007229","doi":null,"title":"Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.","display_name":"Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.","publication_year":2003,"publication_date":"2003-09-15","ids":{"openalex":"https://openalex.org/W2099007229","mag":"2099007229","pmid":"https://pubmed.ncbi.nlm.nih.gov/14519631"},"language":"en","primary_location":{"id":"pmid:14519631","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14519631","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Clinical Trial"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037931237","display_name":"John R. Murren","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Murren","raw_affiliation_strings":["Yale-New Haven Cancer Center, New Haven, Connecticut 06520, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale-New Haven Cancer Center, New Haven, Connecticut 06520, USA","institution_ids":["https://openalex.org/I2802730090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111880602","display_name":"Manuel Modiano","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Manuel Modiano","raw_affiliation_strings":["Arizona Clinical Research Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Arizona Clinical Research Center","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049473619","display_name":"Caroline Clairmont","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I867599234","display_name":"Vion Pharmaceuticals (United States)","ror":"https://ror.org/036dfq243","country_code":"US","type":"company","lineage":["https://openalex.org/I867599234"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Caroline Clairmont","raw_affiliation_strings":["Vion Pharmaceuticals Incorporated"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vion Pharmaceuticals Incorporated","institution_ids":["https://openalex.org/I867599234"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086383195","display_name":"Paula Lambert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I867599234","display_name":"Vion Pharmaceuticals (United States)","ror":"https://ror.org/036dfq243","country_code":"US","type":"company","lineage":["https://openalex.org/I867599234"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paula Lambert","raw_affiliation_strings":["Vion Pharmaceuticals Incorporated"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vion Pharmaceuticals Incorporated","institution_ids":["https://openalex.org/I867599234"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038264812","display_name":"Niramol Savaraj","orcid":"https://orcid.org/0000-0002-7625-1223","observed_orcids":["https://orcid.org/0000-0002-7625-1223"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Niramol Savaraj","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039895409","display_name":"Terry Doyle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I867599234","display_name":"Vion Pharmaceuticals (United States)","ror":"https://ror.org/036dfq243","country_code":"US","type":"company","lineage":["https://openalex.org/I867599234"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Terry Doyle","raw_affiliation_strings":["Vion Pharmaceuticals Incorporated"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vion Pharmaceuticals Incorporated","institution_ids":["https://openalex.org/I867599234"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5007198397","display_name":"Mario Sznol","orcid":"https://orcid.org/0000-0003-4137-9662","observed_orcids":["https://orcid.org/0000-0003-4137-9662"]},"institutions":[{"id":"https://openalex.org/I867599234","display_name":"Vion Pharmaceuticals (United States)","ror":"https://ror.org/036dfq243","country_code":"US","type":"company","lineage":["https://openalex.org/I867599234"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mario Sznol","raw_affiliation_strings":["Vion Pharmaceuticals Incorporated"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vion Pharmaceuticals Incorporated","institution_ids":["https://openalex.org/I867599234"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.5085,"has_fulltext":false,"cited_by_count":108,"citation_normalized_percentile":{"value":0.8076376,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"9","issue":"11","first_page":"4092","last_page":"100"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.6929000020027161,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.6929000020027161,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12827","display_name":"Biochemical and Molecular Research","score":0.0731000006198883,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12356","display_name":"Bioactive Compounds and Antitumor Agents","score":0.039900001138448715,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/triapine","display_name":"triapine","score":0.9980000257492065},{"id":"https://openalex.org/keywords/ribonucleotide-reductase-inhibitors","display_name":"ribonucleotide reductase inhibitors","score":0.9599999785423279},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8560000061988831},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8240000009536743},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8349999785423279},{"id":"https://openalex.org/keywords/leukopenia","display_name":"leukopenia","score":0.9319999814033508},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.6549999713897705},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8790000081062317},{"id":"https://openalex.org/keywords/linear-pharmacokinetics","display_name":"linear pharmacokinetics","score":0.5809999704360962},{"id":"https://openalex.org/keywords/hepatic-adverse-events","display_name":"hepatic adverse events","score":0.6100000143051147},{"id":"https://openalex.org/keywords/hyperbilirubinemia","display_name":"hyperbilirubinemia","score":0.7480000257492065},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.4309999942779541},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.8960000276565552},{"id":"https://openalex.org/keywords/anticancer-agents","display_name":"anticancer agents","score":0.531000018119812},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5720000267028809}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8056472539901733},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7489441633224487},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.7372451424598694},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7125420570373535},{"id":"https://openalex.org/C4710235","wikidata":"https://www.wikidata.org/wiki/Q420089","display_name":"Ribonucleotide reductase","level":4,"score":0.6554434895515442},{"id":"https://openalex.org/C2780873365","wikidata":"https://www.wikidata.org/wiki/Q496812","display_name":"Leukopenia","level":3,"score":0.5511828660964966},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.5471632480621338},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5261901021003723},{"id":"https://openalex.org/C2777334693","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Maximum tolerated dose","level":3,"score":0.5056862831115723},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.4403947591781616},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3833826780319214},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.34595736861228943},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.07497230172157288},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C104292427","wikidata":"https://www.wikidata.org/wiki/Q899781","display_name":"Protein subunit","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D001247","descriptor_name":"Asthenia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008657","descriptor_name":"Metabolic Clearance Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D012264","descriptor_name":"Ribonucleotide Reductases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D013882","descriptor_name":"Thiosemicarbazones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013882","descriptor_name":"Thiosemicarbazones","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D013882","descriptor_name":"Thiosemicarbazones","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:14519631","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14519631","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Clinical Trial"},{"id":"mag:2099007229","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14519631","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W61704258","https://openalex.org/W76119661","https://openalex.org/W1508340483","https://openalex.org/W1510505825","https://openalex.org/W1535189264","https://openalex.org/W1555309303","https://openalex.org/W1795204252","https://openalex.org/W1894026278","https://openalex.org/W1999995381","https://openalex.org/W2019227458","https://openalex.org/W2027846898","https://openalex.org/W2037984981","https://openalex.org/W2062223022","https://openalex.org/W2066680166","https://openalex.org/W2066969026","https://openalex.org/W2083315452","https://openalex.org/W2085972813","https://openalex.org/W2138132734","https://openalex.org/W2141086589","https://openalex.org/W2146292149","https://openalex.org/W2171216272","https://openalex.org/W2402185405","https://openalex.org/W2461318160"],"related_works":["https://openalex.org/W2015576599","https://openalex.org/W2084590133","https://openalex.org/W2264501050","https://openalex.org/W2025399633","https://openalex.org/W2064728753","https://openalex.org/W2118226539","https://openalex.org/W2265467041","https://openalex.org/W2555680128","https://openalex.org/W2589286309","https://openalex.org/W2604986078"],"abstract_inverted_index":{"PURPOSE:":[0],"A":[1,156],"Phase":[2,431,459],"I":[3,460],"study":[4,93,128],"in":[5,81,102,149,202,262,278,280,289,293,303,305,404],"patients":[6,160,195,218],"with":[7,230,340,439,463],"advanced":[8],"cancer":[9],"was":[10,34,53,57,73,95,129,188,296,300,316,363],"conducted":[11],"to":[12,59,97,131,209,337,421,443],"determine":[13,132],"the":[14,63,87,92,106,127,133,138,164,169,189,203,223,242,270,322,329,354,359,424,445,456],"safety,":[15],"pharmacokinetics,":[16],"and":[17,135,207,249,255,257,264,285,299,328,418],"maximum":[18],"tolerated":[19],"dose":[20,52,72,90,100,123,140,165,181,324,379],"of":[21,28,83,109,124,137,153,158,168,182,274,344,353,361,380,414,427,447,458],"Triapine,":[22],"a":[23,67,77,110,122,180,341,378,440],"new,":[24],"potent":[25],"small-molecule":[26],"inhibitor":[27],"ribonucleotide":[29,428],"reductase.":[30],"EXPERIMENTAL":[31],"DESIGN:":[32],"Triapine":[33,308,362,375],"administered":[35,141,355,376],"by":[36,214,383],"2-h":[37,384],"i.v.":[38,385],"infusion":[39,386],"daily":[40,142,226,387],"for":[41,143,227,241,388,411],"5":[42,54,144,228,389],"days.":[43],"Courses":[44],"were":[45,176,219,245,258,372],"repeated":[46,232],"every":[47,146,233],"4":[48,277,449],"weeks.":[49,235],"The":[50,71,236,451],"starting":[51],"mg/m(2)/day,":[55,126],"but":[56,436],"reduced":[58],"2":[60,113,147,234,288],"mg/m(2)/day":[61,89],"after":[62,205],"first":[64,107,177],"patient":[65],"developed":[66],"hepatic":[68],"adverse":[69,114,174],"event.":[70],"subsequently":[74,220],"escalated":[75],"using":[76],"modified":[78],"Fibonacci":[79],"scheme":[80],"cohorts":[82,104],"3-6":[84],"patients.":[85,154],"After":[86],"12":[88],"level,":[91],"design":[94],"amended":[96,130],"permit":[98],"100%":[99],"escalation":[101,166],"single-patient":[103],"until":[105],"episode":[108],"drug-related":[111,173],"grade":[112,171,210,260,291,301,448],"event":[115],"or":[116,212,369],"dose-limiting":[117],"toxicity":[118,191,268],"(DLT).":[119],"On":[120],"reaching":[121],"96":[125,183,381],"safety":[134,398,452],"tolerability":[136],"96-mg/m(2)":[139,224],"days":[145,390],"weeks":[148],"an":[150,392,396],"expanded":[151],"cohort":[152],"RESULTS:":[155],"total":[157],"32":[159],"received":[161],"treatment.":[162],"During":[163],"phase":[167],"study,":[170],"2-4":[172],"events":[175],"observed":[178,192],"at":[179,197,222,281,321,377],"mg/m(2)/day.":[184],"Grade":[185],"3-4":[186,302],"leukopenia":[187,275],"primary":[190],"among":[193],"four":[194],"treated":[196,221],"this":[198],"dose,":[199,225,356],"which":[200],"occurred":[201],"week":[204],"treatment":[206],"resolved":[208],"1":[211,346],"lower":[213],"day":[215,417],"15.":[216],"Fifteen":[217],"days,":[229],"courses":[231],"most":[237],"common":[238,298],"nonhematological":[239],"toxicities":[240],"latter":[243],"schedule":[244,272,394,442],"asthenia,":[246],"fever,":[247],"nausea":[248],"vomiting,":[250],"mucositis,":[251],"decreased":[252],"serum":[253],"bicarbonate,":[254],"hyperbilirubinemia,":[256],"predominantly":[259],"1-2":[261],"severity":[263,304],"rapidly":[265],"reversible.":[266],"Hematological":[267],"on":[269,391],"every-other-week":[271,393],"consisted":[273],"(grade":[276,287],"93%":[279],"least":[282],"one":[283],"course)":[284],"anemia":[286],"71%,":[290],"3":[292,338],"22%).":[294],"Thrombocytopenia":[295],"less":[297],"only":[306],"22%.":[307],"showed":[309],"linear":[310],"pharmacokinetic":[311],"behavior":[312],"although":[313],"interpatient":[314],"variability":[315],"relatively":[317],"high.":[318],"Peak":[319],"concentrations":[320,401,408],"96-mg/m(2)/day":[323],"averaged":[325,351],"8":[326],"microM,":[327],"mean":[330],"elimination":[331,360],"T(1/2)":[332],"ranged":[333],"from":[334],"35":[335],"min":[336],"h,":[339],"median":[342],"value":[343],"approximately":[345],"h.":[347],"Cumulative":[348],"urinary":[349],"recovery":[350],"1-3%":[352],"suggesting":[357],"that":[358,402],"primarily":[364],"through":[365],"metabolism.":[366],"No":[367],"partial":[368],"complete":[370],"responses":[371],"observed.":[373],"CONCLUSIONS:":[374],"mg/m(2)":[382],"demonstrates":[395],"acceptable":[397],"profile.":[399],"Serum":[400],"surpass":[403],"vitro":[405],"tumor":[406],"growth-inhibitory":[407],"are":[409,419,434],"achieved":[410],"brief":[412],"periods":[413],"time":[415],"each":[416],"sufficient":[420],"produce":[422],"myelosuppression,":[423],"expected":[425],"consequence":[426],"reductase":[429],"inhibition.":[430],"II":[432],"trials":[433,462],"indicated":[435],"will":[437],"proceed":[438],"daily-for-4-days":[441],"reduce":[444],"incidence":[446],"leukopenia.":[450],"profile":[453],"also":[454],"supports":[455],"initiation":[457],"combination":[461],"other":[464],"anticancer":[465],"agents.":[466]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":11}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}